Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Actinogen Medical ( (AU:ACW) ) has shared an announcement.
Actinogen Medical has highlighted that two tranches of unlisted options, ACWOPT10 and ACWOPT11, each exercisable at $0.0375, are due to expire in September 2026, and reminded holders to allow sufficient time for exercise and payment processing. The company noted that CEO Dr Steven Gourlay has exercised his unlisted options in full, injecting $91,599.26 of additional capital and bringing his personal equity contributions to more than $2.5 million, underscoring management’s confidence ahead of key Alzheimer’s trial data.
Management framed the option expiry against the backdrop of the company’s XanaMIA Phase 2b/3 Alzheimer’s trial, which has completed recruitment, passed an independent safety and futility review and is scheduled to deliver topline results in November 2026. The update reinforces Actinogen’s positioning in the neurodegenerative and neuropsychiatric treatment space, where its cortisol‑modulating drug Xanamem has already shown promising clinical activity in Alzheimer’s and depression, potentially heightening investor interest as the pivotal data milestone approaches.
The most recent analyst rating on (AU:ACW) stock is a Buy with a A$0.08 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.
More about Actinogen Medical
Actinogen Medical is an ASX‑listed biotechnology company developing Xanamem, a novel therapy targeting dysregulated brain cortisol to treat neurological and neuropsychiatric diseases. Its main focus is Alzheimer’s disease, with additional work in treatment‑resistant depression and potential future indications such as Fragile X Syndrome and other cognitive disorders.
The company’s lead asset Xanamem is a once‑daily pill designed to inhibit the 11β‑HSD1 enzyme in the brain, aiming to reduce cortisol‑driven neuronal damage without disrupting systemic cortisol production. Actinogen has run multiple phase 2 trials, including the XanaMIA Alzheimer’s study and the XanaCIDD depression trial, which showed significant benefits on depressive symptoms and further validated its cortisol‑control mechanism.
Average Trading Volume: 2,837,323
Technical Sentiment Signal: Buy
Current Market Cap: A$168.7M
For an in-depth examination of ACW stock, go to TipRanks’ Overview page.